XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue
 3 Months Ended
Mar. 31, 2018
Revenue [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]
The cumulative effect of the changes made to our condensed consolidated January 1, 2018 balance sheet for the adoption of ASC 606 was as follows:
($ in millions)
Balance at December 31, 2017
 
Adjustments Due to ASC 606
 
Balance at January 1, 2018
Assets:
 
 
 
 
 
Accounts receivable, net
$
253.2

 
$
25.0

 
$
278.2

Inventories
215.2

 
(20.8
)
 
194.4

Other current assets
39.2

 
(8.4
)
 
30.8

 
 
 
 
 
 
Liabilities and Equity:
 
 
 
 
 
Other current liabilities
$
77.0

 
$
(13.7
)
 
$
63.3

Deferred income taxes
10.4

 
3.0

 
13.4

Other long-term liabilities
42.6

 
(4.9
)
 
37.7

Retained earnings
1,178.2

 
11.4

 
1,189.6

The impact of the adoption of ASC 606 on our condensed consolidated income statement for the three months ended March 31, 2018 was as follows:
($ in millions)
As Reported
 
Balances without Adoption of ASC 606
 
Effects of Change (Lower)/Higher
Net sales
$
415.7

 
$
418.3

 
$
(2.6
)
Cost of goods and services sold
281.3

 
282.7

 
(1.4
)
Other expense
3.1

 
3.0

 
0.1

Income tax expense
12.5

 
12.9

 
(0.4
)
Net income
$
43.6

 
$
44.5

 
$
(0.9
)
The impact of the adoption of ASC 606 on our condensed consolidated balance sheet as of March 31, 2018 was as follows:
($ in millions)
As Reported
 
Balances without Adoption of ASC 606
 
Effects of Change Higher/(Lower)
Assets:
 
 
 
 
 
Accounts receivable, net
$
290.4

 
$
267.6

 
$
22.8

Inventories
215.7

 
234.7

 
(19.0
)
Other current assets
37.6

 
46.5

 
(8.9
)
 
 
 
 
 
 
Liabilities and Equity:
 
 
 
 
 
Other current liabilities
$
69.6

 
$
83.0

 
$
(13.4
)
Deferred income taxes
12.3

 
9.7

 
2.6

Other long-term liabilities
35.6

 
40.4

 
(4.8
)
Retained earnings
1,222.8

 
1,212.3

 
10.5
Disaggregation of Revenue [Table Text Block]
The following table presents the approximate percentage of our net sales by market group:
 
Three Months Ended
March 31,
 
2018
 
2017 (1)
Biologics
21
%
 
22
%
Generics
21
%
 
20
%
Pharma
36
%
 
38
%
Contract-Manufactured Products
22
%
 
20
%
 
100
%
 
100
%
(1) As noted above, prior period amounts have not been adjusted under the modified retrospective method.
The following table presents the approximate percentage of our net sales by product category:
 
Three Months Ended
March 31,
 
2018
 
2017 (1)
High-Value Components
41
%
 
43
%
Standard Packaging
34
%
 
34
%
Delivery Devices
3
%
 
3
%
Contract-Manufactured Products
22
%
 
20
%
 
100
%
 
100
%
(1) As noted above, prior period amounts have not been adjusted under the modified retrospective method.
The following table presents the approximate percentage of our net sales by geographic location:
 
Three Months Ended
March 31,
 
2018
 
2017 (1)
Americas
45
%
 
52
%
Europe, Middle East, Africa
47
%
 
41
%
Asia Pacific
8
%
 
7
%
 
100
%
 
100
%
(1) As noted above, prior period amounts have not been adjusted under the modified retrospective method.
Change in Contract with Customer, Asset and Liability [Abstract]
The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:
 
($ in millions)
Contract assets, December 31, 2017
$
7.5

Contract assets, March 31, 2018
6.4

Change in contract assets - (decrease) increase
$
(1.1
)
 
 
Deferred income, December 31, 2017
$
(33.6
)
Deferred income, March 31, 2018
(22.1
)
Change in deferred income - decrease (increase)
$
11.5